Tag Archives: Investors

RESI San Diego Panel Announcement – Diagnostic Investors

4 May

By Michael Quigley, VP of Market Research, LSN

mike-2

Fundraising for diagnostics companies, like most early stage healthcare technologies, is no easy task. A relative lack of a thriving M&A/IPO exit environment compared to other life science sectors along with high profile flops in the space has made some investors wary. However there exists a significant need for advancement in the field of diagnostics. From pharma companies wanting novel biomarkers to more accurately stratify patients for clinical trials, to the rise of personalized therapies via genomic testing, there’s a growing need for more accurate diagnostics and in many disease areas they do not currently exist.

In addition, many traditionally software or technology focused VCs and major strategics are looking to utilize their expertise to advance bioinformatic breakthroughs. While some these “new” healthcare investors have learned the hard way the difference between healthcare and consumer tech, as they continue to learn they will likely represent an increase of value added capital to the space.

In this session, we will hear from 5 Investors including VCs, large corporations and angels with experience and intent to invest in early stage diagnostics companies. The speakers will cover the types of investments they are looking to make and share insights they have learned working within the space. For any entrepreneur looking to raise capital for a diagnostic technology this is a must attend panel. Look below to see the speakers for yourself. We hope to see you in San Diego.

Tags: , , , , , , ,

Key Stakeholders Share the Value of RESI for Early Stage Investors and Startups

27 Apr

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-new

In San Diego on June 19th, the Redefining Early Stage Investments (RESI) Conference will bring a new, early stage focused discussion venue for startups and investors who are visiting BIO week and want more opportunities to connect. What makes RESI different? At our last event, RESI on MaRS in Toronto, we asked our key stakeholders this question and here’s what they told us.

Ying Tam – Head of Digital Health – MaRS Discovery District

“All the research says that one of the critical elements for an entrepreneur ecosystem, especially in health, is funding and investment. It takes a long time to nurture a health company, to get it to market and commercialization and scale. So, investment is critical for the development of a startup in health. RESI brings in a whole set of investors from across North America and across the world.”

Rebecca Yu – Head of JLABS @ Toronto – Johnson & Johnson Innovation JLABS

“RESI attracts many repeat attendees, and that speaks to me that there’s a story, there’s something here. There’s great stuff happening here for entrepreneurs. There’s early stage companies from across Canada, from pharmaceuticals to medical devices to consumer health, and of course there’s a big digital health and AI presence here in Toronto. That’s why JLABS and J&J are here. We play in all the sectors, we partner with different groups within this ecosystem, and we see LSN/RESI as a key partner as well, to bring investors to this ecosystem.”

Richard Soll – Senior Vice President, International Discovery Service Unit – WuXi AppTec

“The RESI conference is an opportunity to help out these early stage companies such that they can achieve inflection points. If I can identify companies early, then I might become a vendor of choice for them. Getting in early becomes an important objective for me. When I come to a conference like RESI, I come to these early stage companies who are really looking for partnering with investors here, but also get an opportunity to introduce WuXi to them as well.”

RESI attendees can book up to 16 meetings with investors in one day, right at the start of BIO Week. If you want to take this opportunity to start your BIO with a bang, register now.

Tags: , , , , , , ,

RESI Panel Announcement – Diagnostic Investors

30 Mar

By Lucy Parkinson, Director of Research, LSN

Diagnostics is a challenging landscape for fundraising and commercialization; however, the sector attracts interest and backing from a wide variety of stakeholders. There are many unmet needs in the sector, from finding new disease biomarkers to improving monitoring of progressive diseases.

The range of diagnostic investors attending RESI on MaRS next Tuesday provide testament to this varied landscape, with interest in novel diagnostic technologies coming from major pharma and device companies, diagnostic service providers, venture investors, and government organizations. RESI will bring the diagnostics world together for a panel discussion, moderated by Bob Williams, Vice President, Business Development and Innovation – Bracco Diagnostics, and featuring:

These investors will introduce their own specific angle on the diagnostics sector, and will cover what they look for in an investment opportunity in this sector. Panelists will also provide advice on how to make a new diagnostic catch their attention as an investable product. If you’d like to hear the advice of these experts at RESI, there’s still time to sign up.

Tags: , , , , , ,

Healthcare IT Investors Share Their Strategies at RESI on MaRS

16 Mar

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Healthcare IT entrepreneurs, as opposed to biotech/medtech entrepreneurs, enjoy some favorable realities when it comes to successfully launching and sustaining a new venture. However, even though software and healthcare IT companies require far less capital than a biopharmaceutical product or medical device to get up and running, investors tend to place an emphasis on market penetration and traction, often the rate limiting step for these startups. A key to overcoming this hurdle is healthy ecosystem with innovative institutions willing to put programs in place to help new digital health technologies enter the marketplace and refine their product.

Canada is embracing digital health and the impact it can have on the public, patients and the healthcare system at large. Toronto, as the epicenter of Canadian healthcare and innovation, is naturally working to catalyze venture creation in healthcare IT and will host the RESI conference and a panel of venture investors active in the space.

The session will feature the following investors:

By registering for RESI on MaRS, you’ll be able to listen to the Healthcare IT panel live, interact with the investors and experience numerous opportunities to expand your network.

Tags: , , , , ,

RESI@MaRS Panel Announcement: Early Stage Therapeutic Investors

9 Mar

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Despite therapeutic companies’ high-risk development timeline, investors continue to remain focused on investing in biotechnology, seeing its long-term impact and enormous potential in the healthcare industry. Along with the technology, entrepreneurs need to also consider capital intensity, fundraising and milestone timeline, management team, and endpoint selections, among other topics beyond the science.

LSN has assembled five active investors specifically interested in early-stage biotech therapeutics for RESI Toronto, occurring on April 4th. Held in the heart of Canada’s healthcare innovation hub, MaRS Discovery District.

The Early Stage Therapeutic Investors Panel will be moderated by Mark Day, Head, CNS Virtual Discovery of Purdue Pharma, and will be joined by:

The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the investment trends; the investor’s perspective when approaching a deal in a high-risk space; and note-worthy advice to entrepreneurs on the best way to approach and work with investors such as themselves.09

This is a tremendous opportunity for biotech life science entrepreneurs and investors to meet and develop relationships in person. Register for RESI@MaRS now so you don’t miss the chance.

Tags: , , , , , ,

Meet with Asia Pacific Investors at RESI

2 Mar

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

A rising number of investors and business delegations from the Asia Pacific region are traveling around the world in search for healthcare innovations. The RESI conference team is pleased to invite a panel of Asia Pacific investors to discuss their investment strategies.

Asia Pacific Investors come in different shape and forms. Private funds are searching for exponential return on investment. Pharmaceutical and research organizations look for a strategic fit with their portfolio. Traditional industry corporations look to expand into healthcare.

As major North American hotbeds are getting crowded with foreign investors in recent years, emerging life science hubs such as Toronto have become attractive destinations for their quality startups in a less competitive scene.

RESI attendees will have a unique opportunity to meet with these groups face-to-face.  The session will feature the following:

Tags: , , , ,

RESI on MaRS Panel Announcement: Corporate Venture Capital

2 Mar

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation, an exit partner; however, attracting and concentrating talent, providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the second time and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by John Gustofson, Senior Director, Abbvie Ventures, this panel will feature:

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

Tags: , , , , , , ,

← Older Entries
Newer Entries →